Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-040980
Filing Date
2023-11-14
Accepted
2023-11-14 15:03:09
Documents
68
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1866973
2 ex31-1.htm EX-31.1 15993
3 ex31-2.htm EX-32.1 7981
  Complete submission text file 0001493152-23-040980.txt   9195619

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ppcb-20230930.xsd EX-101.SCH 62184
5 XBRL CALCULATION FILE ppcb-20230930_cal.xml EX-101.CAL 65913
6 XBRL DEFINITION FILE ppcb-20230930_def.xml EX-101.DEF 311695
7 XBRL LABEL FILE ppcb-20230930_lab.xml EX-101.LAB 510065
8 XBRL PRESENTATION FILE ppcb-20230930_pre.xml EX-101.PRE 420309
62 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1419720
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-54878 | Film No.: 231404750
SIC: 2834 Pharmaceutical Preparations